Phase III trial of ursodeoxycholic acid to prevent colorectal adenoma recurrence

Journal of the National Cancer Institute

Volumn 97, Issue 11, 2005, Pages 846-853

  Alberts, David S ^a,b   Martínez, María Elena ^a,b   Hess, Lisa M ^b   Einspahr, Janine G ^a,b   Green, Sylvan B ^a,b   Bhattacharyya, A K ^a,b   Guillen, Jose ^b   Krutzsch, Mary ^b   Batta, Ashok K ^d   Salen, Gerald ^d   Fales, Liane ^b   Koonce, Kris ^b   Parish, Dianne ^b   Clouser, Mary ^b   Roe, Denise ^a,b   Lance, Peter ^a,b,c  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c University of Arizona   (United States)

^d RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; URSODEOXYCHOLIC ACID; ANTINEOPLASTIC AGENT;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CANCER PREVENTION; CANCER RISK; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COLORECTAL ADENOMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DYSPLASIA; FEMALE; GASTROINTESTINAL TOXICITY; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; NAUSEA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; STROKE; TREATMENT OUTCOME; TUMOR RECURRENCE; VOMITING; ADENOMA; CANCER INVASION; COLORECTAL TUMOR; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY;

ADENOMA; ADULT; AGED; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; TREATMENT OUTCOME; URSODEOXYCHOLIC ACID;

EID: 20544476450     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/dji144     Document Type: Article

References (40)

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. Cancer statistics, 2004. CA Cancer J Clin 2005;55:10-30.
2. Reddy BS, Wynder EL. Metabolic epidemiology of colon cancer. Fecal bile acids and neutral sterols in colon cancer patients and patients with adenomatous polyps. Cancer 1977;39:2533-9.
3. Moorehead RJ, Campbell GR, Donaldson JD, McKelvey ST. Relationship between duodenal bile acids and colorectal neoplasia. Gut 1987;28:1454-9.
4. Morvay K, Szentleleki K, Torok G, Pinter A, Borzsonyj M, Nawroth R. Effect of change of fecal bile acid excretion achieved by operative procedures on 1,2-dimethylhydrazine-induced colon cancer in rats. Dis Colon Rectum 1989;32:860-3.
5. Bayerdorffer E, Mannes GA, Richter WO, Ochsenkuhn T, Wiebecke B, Kopcke W, et al. Increased serum deoxycholic acid levels in men with colorectal adenomas. Gastroenterology 1993;104:145-51.
6. Bayerdorffer E, Mannes GA, Ochsenkuhn T, Dirschedl P, Wiebecke B, Paumgartner G. Unconjugated secondary bile acids in the serum of patients with colorectal adenomas. Gut 1995;36:268-73.
7. Ochsenkuhn T, Bayerdorffer E, Meining A, Schinkel M, Thiede C, Nussler V, et al. Colonic mucosal proliferation is related to serum deoxycholic acid levels. Cancer 1999;85:1664-9.
8. Martinez JD, Stratagoules ED, LaRue JM, Powell AA, Gause PR, Craven MT, et al. Different bile acids exhibit distinct biological effects: the tumor promoter deoxycholic acid induces apoptosis and the chemopreventive agent ursodeoxycholic acid inhibits cell proliferation. Nutr Cancer 1998;31: 111-8.
9. Qiao D, Chen W, Stratagoules ED, Martinez JD. Bile acid-induced activation of activator protein-1 requires both extracellular signal-regulated kinase and protein kinase C signaling. J Biol Chem 2000;275:15090-8.
10. Zhang F, Subbaramaiah K, Altorki N, Dannenberg AJ. Dihydroxy bile acids activate the transcription of cyclooxygenase-2. J Biol Chem 1998;273: 2424-8.
11. Payne CM, Crowley C, Washo-Stultz D, Briehl M, Bernstein H, Bernstein C, et al. The stress-response proteins poly(ADP-ribose) polymerase and NF-kappaB protect against bile salt-induced apoptosis. Cell Death Differ 1998;5:623-36.
12. Wargovich MJ, Eng VW, Newmark HL, Bruce WR. Calcium ameliorates the toxic effect of deoxycholic acid on colonic epithelium. Carcinogenesis 1983;4:1205-7.
13. Bull AW, Marnett LJ, Dawe EJ, Nigro ND. Stimulation of deoxythymidine incorporation in the colon of rats treated intrarectally with bile acids and fats. Carcinogenesis 1983;4:207-10.
14. Lapre JA, Termont DS, Groen AK, Van der Meer R. Lytic effects of mixed micelles of fatty acids and bile acids. Am J Physiol 1992;263(3 Pt 1): G333-7.
15. Watabe J, Bernstein H. The mutagenicity of bile acids using a fluctuation test. Mutat Res 1985;158:45-51.
16. Friedman EA. A multistage model for human colon carcinoma development from tissue culture studies. In: Ingall JRF, Mastromarino, A.J., editor. Carcinoma of the large bowel and its precursors. New York (NY): Alan R. Liss, Inc.; 1985. p. 175-86.
17. McMillan L, Butcher S, Wallis Y, Neoptolemos JP, Lord JM. Bile acids reduce the apoptosis-inducing effects of sodium butyrate on human colon adenoma (AA/C1) cells: implications for colon carcinogenesis. Biochem Biophys Res Commum 2000;273:45-9.
18. Qiao D, Stratagouleas ED, Martinez JD. Activation and role of mitogen-activated protein kinases in deoxycholic acid-induced apoptosis. Carcinogenesis 2001;22:35-41.
19. Im E, Martinez JD. Ursodeoxycholic acid (UDCA) can inhibit deoxycholic acid (DCA)-induced apoptosis via modulation of EGFR/Raf-1/ERK signaling in human colon cancer cells. J Nutr 2004;134:483-6.
20. Earnest DL, Holubec H, Wali RK, Jolley CS, Bissonette M, Bhattacharyya AK, et al. Chemoprevention of azoxymethane-induced colonic carcinogenesis by supplemental dietary ursodeoxycholic acid. Cancer Res 1994;54:5071-4.
21. Brasitus TA. Primary chemoprevention strategies for colorectal cancer: ursodeoxycholic acid and other agents. Gastroenterology 1995;109: 2036-8.
22. Wali RK, Frawley BP Jr, Hartmann S, Roy HK, Khare S, Scaglione-Sewell BA, et al. Mechanism of action of chemoprotective ursodeoxycholate in the azoxymethane model of rat colonic carcinogenesis: potential roles of protein kinase C-alpha, -beta II, and -zeta. Cancer Res 1995;55:5257-64.
23. Im E, Akare S, Powell AA, Martinez JD. Ursodeoxycholic acid can suppress deoxycholic acid induced apoptosis by stimulating Akt/PKB-dependent survival signaling. Nutr Cancer 2005;51:110-6.
24. Tung BY, Emond MJ, Haggitt RC, Bronner MP, Kimmey MB, Kowdley KV, et al. Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med 2001;134:89-95.
25. Serfaty L, Deleusse A, Rosmorduc R, Desaint B, Flejou JF, Chazouilleres O, et al. Ursodeoxycholic acid therapy and the risk of colorectal adenoma. Hepatology 2003;38:203-9.
26. Pardi DS, Loftus EV Jr, Kremers WK, Keach J, Lindor KD. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 2003;124:889-93.
27. Serfaty L, De Leusse A, Rosmorduc O, Desaint B, Flejou JF, Chazouilleres O, et al. Ursodeoxycholic acid therapy and the risk of colorectal adenoma in patients with primary biliary cirrhosis: an observational study. Hepatology 2003;38:203-9.
28. Hess LM, Krutzsch MF, Guillen J, Chow HH, Einspahr J, Batta AK, et al. Results of a phase I multiple-dose clinical study of ursodeoxycholic Acid. Cancer Epidemiol Biomarkers Prev 2004;13:861-7.
29. Alberts DS, Einspahr JG, Earnest DL, Krutzsch ME, Lin P, Hess LM, et al. Fecal bile acid concentrations in a subpopulation of the wheat bran fiber colon polyp trial. Cancer Epidemiol Biomarkers Prev 2003;12:197-200.
30. Batta AK, Salen G, Holubec H, Brasitus TA, Alberts D, Earnest DL. Enrichment of the more hydrophilic bile acid ursodeoxycholic acid in the fecal water-soluble fraction after feeding to rats with colon polyps. Cancer Res 1998;58:1684-7.
31. Batta AK, Salen G, Rapole KR, Batta M, Batta P, Alberts D, et al. Highly simplified method for gas-liquid chromatographic quantitation of bile acids and sterols in human stool. J Lipid Res 1999;40:1148-54.
32. Munkholm P. The incidence and prevalence of colorectal cancer in inflammatory bowel disease. Aliment Pharmacol Ther 2003;18 Suppl 2:1-5.
33. Rutter M, Saunders B, Wilkinson K, Rumbles S, Schofield G, Kamm M, et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 2004;126:451-9.
34. Bernstein CN. A balancing view: dysplasia surveillance in ulcerative colitis - sorting the pro from the con. Am J Gastroenterol 2004;99: 1636-7.
35. Roy HK, Bissonnette M, Frawley BP Jr, Wali RK, Niedziela SM, Earnest D, et al. Selective preservation of protein kinase C-zeta in the chemoprevention of azoxymethane-induced colonic tumors by piroxicam. FEBS Lett 1995;366:143-5.
36. Ikegami T, Matsuzaki Y, Shoda J, Kano M, Hirabayashi N, Tanaka N. The chemopreventive role of ursodeoxycholic acid in azoxymethane-treated rats: suppressive effects on enhanced group II phospholipase A2 expression in colonic tissue. Cancer Lett 1998;134:129-39.
37. Jacoby RF, Cole CE, Hawk ET, Lubet RA. Ursodeoxycholate/Sulindac combination treatment effectively prevents intestinal adenomas in a mouse model of polyposis. Gastroenterology 2004;127:838-44.
38. Martinez ME, Reid ME, Guillen-Rodriguez J, Marshall JR, Sampliner R, Aickin M, et al. Design and baseline characteristics of study participants in the Wheat Bran Fiber trial. Cancer Epidemiol Biomarkers Prev 1998;7:813-6.
39. Baron JA, Beach M, Mandel JS, van Stolk RU, Haile RW, Sandler RS, et al. Calcium supplements for the prevention of colorectal adenomas. Calcium Polyp Prevention Study Group. New Engl J Med 1999;340:101-7.
40. Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R, et al. A randomized trial of aspirin to prevent colorectal adenomas. New Engl J Med 2003;348:891-9.